PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer

BACKGROUND: Vaginal brachytherapy is currently recommended as adjuvant treatment in patients with high-intermediate risk endometrial cancer to maximize local control and has only mild side effects and no or limited impact on quality of life. However, there is still considerable overtreatment and als...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Heerik, Anne Sophie V M, Horeweg, Nanda, Nout, Remi A, Lutgens, Ludy C H W, van der Steen-Banasik, Elzbieta M, Westerveld, G Henrike, van den Berg, Hetty A, Slot, Annerie, Koppe, Friederike L A, Kommoss, Stefan, Mens, Jan Willem M, Nowee, Marlies E, Bijmolt, Stefan, Cibula, David, Stam, Tanja C, Jurgenliemk-Schulz, Ina M, Snyers, An, Hamann, Moritz, Zwanenburg, Aleida G, Coen, Veronique L M A, Vandecasteele, Katrien, Gillham, Charles, Chargari, Cyrus, Verhoeven-Adema, Karen W, Putter, Hein, van den Hout, Wilbert B, Wortman, Bastiaan G, Nijman, Hans W, Bosse, Tjalling, Creutzberg, Carien L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788476/
https://www.ncbi.nlm.nih.gov/pubmed/33046573
http://dx.doi.org/10.1136/ijgc-2020-001929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788476/
https://www.ncbi.nlm.nih.gov/pubmed/33046573
http://dx.doi.org/10.1136/ijgc-2020-001929

Ejemplares similares